文献速递肿瘤 PET/CT放射性药物与辐射防护

LiDAR配准自由臂SPECT联合近红外荧光实现示踪剂高摄取腹股沟淋巴结空间定位的临床可行性研究

LiDAR-registered freehand SPECT combined with NIR-fluorescence enables spatial localisation of tracer-avid inguinal lymph nodes: A clinical feasibility study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-21

LiDAR/fhSPECT在38/40个孤立淋巴结中定位放射性热点了,与常规γ探头评估一致,NIR荧光在全部40个淋巴结中检测到荧光信号。在3例ILND标本中,LiDAR/fhSPECT定位了全部6个术前SPECT/CT识别的示踪剂高摄取热点。

要点

  • LiDAR配准fhSPECT联合NIR荧光可在离体标本中实现示踪剂高摄取淋巴结的三维空间定位。
  • 在孤立淋巴结中LiDAR/fhSPECT定位38/40个放射性热点,与常规γ探头评估一致。
  • 在ILND标本中LiDAR/fhSPECT定位全部6个热点,优于常规γ探头(4个)和NIR荧光(5个)。

核心结论

  • LiDAR配准三维表面映射为放射性和荧光分子成像信号提供了解剖背景,能够在复杂离体ILND标本中定位示踪剂高摄取淋巴结。
  • 这些发现支持混合示踪剂摄取空间增强定位的可行性,并需要在更大规模研究中验证。

研究设计与样本

  • 切除标本先进行常规离体评估,随后进行LiDAR配准fhSPECT联合配准NIR荧光成像,三维模型与常规离体评估、术前成像及组织病理学结果比较。

主要发现

  • 共40个孤立示踪剂高摄取淋巴结和3个ILND标本接受离体评估。
  • LiDAR/fhSPECT在38/40个孤立淋巴结中定位放射性热点,与常规γ探头评估一致;常规和LiDAR配准NIR荧光成像均在全部40个淋巴结中检测到荧光信号。
  • 3例ILND手术中,术前SPECT/CT在解剖切除模板内识别6个示踪剂高摄取热点,常规γ探头和NIR荧光分别仅检测到4个和5个热点,而LiDAR/fhSPECT在相应切除标本中定位全部6个热点。
  • 组织病理学识别6个肿瘤阳性淋巴结,均为混合示踪剂高摄取并被LiDAR/fhSPECT有效定位。

临床怎么用

  • LiDAR配准fhSPECT联合NIR荧光可为离体淋巴结标本中示踪剂高摄取淋巴结提供三维空间定位信息,辅助常规离体评估。
  • 该技术尚处于临床可行性验证阶段,需在更大规模研究中验证后方可常规用于指导淋巴结定位。

局限性

  • 研究为临床可行性研究,未报告诊断效能指标如灵敏度、特异度等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Conventional ex vivo molecular assessment of nodal specimens lacks three-dimensional (3D) spatial context, making localisation of tracer-avid sentinel nodes (SNs) within large en bloc inguinal lymph node dissection (ILND) specimens challenging. We evaluated the technical feasibility of combining light detection and ranging (LiDAR)-registered freehand SPECT (fhSPECT) with near-infrared (NIR) fluorescence imaging for spatially augmented localisation of hybrid tracer uptake in solitary SNs and SNs residing within ILND specimens. METHODS: Fourteen patients with penile cancer (25 cN0 groins; 3 cN1 groins) underwent radio- and fluorescence-guided lymph node (LN) surgery following preoperative lymphoscintigraphy and SPECT/CT. Resected specimens underwent conventional ex vivo assessment, followed by LiDAR-registered fhSPECT with co-registered NIR-fluorescence imaging. These 3D models were compared with conventional ex vivo assessments, preoperative imaging, and histopathological outcomes. RESULTS: In total, 40 solitary tracer-avid LNs and 3 ILND specimens underwent ex vivo assessment. LiDAR/fhSPECT localised radioactive hotspots in 38/40 solitary LNs, consistent with conventional gamma probe assessment, while both conventional and LiDAR-registered NIR-fluorescence imaging detected fluorescent signal in all 40 LNs. Among the 3 ILND procedures, preoperative SPECT/CT identified 6 tracer-avid hotspots within the anatomical resection template. Conventional gamma probe and NIR-fluorescence detected only 4 and 5 hotspots, respectively, whereas LiDAR/fhSPECT localised all 6 hotspots in the corresponding resected specimens. Histopathology identified 6 tumour-positive LNs, all of which were hybrid tracer-avid and effectively localised by LiDAR/fhSPECT. CONCLUSION: LiDAR-registered 3D surface mapping provided anatomical context to radioactive and fluorescent molecular imaging signals, enabling localisation of tracer-avid LNs in complex ex vivo ILND specimens. These findings support the feasibility of spatially augmented localisation of hybrid tracer uptake and warrant validation in larger studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Verdijk RWA, Pisano G, van Oosterom MN, et al. LiDAR-registered freehand SPECT combined with NIR-fluorescence enables spatial localisation of tracer-avid inguinal lymph nodes: A clinical feasibility study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42477145. doi:10.1007/s00259-026-08075-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。